These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

307 related articles for article (PubMed ID: 23863723)

  • 1. [Chemotherapy for GI and pancreatic NETs].
    Doi T
    Gan To Kagaku Ryoho; 2013 Jul; 40(7):838-42. PubMed ID: 23863723
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Update on novel therapies for pancreatic neuroendocrine tumors.
    Oberstein PE; Saif MW
    JOP; 2012 Jul; 13(4):372-5. PubMed ID: 22797392
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pancreatic neuroendocrine tumors: entering a new era.
    Oberstein PE; Remotti H; Saif MW; Libutti SK
    JOP; 2012 Mar; 13(2):169-73. PubMed ID: 22406593
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neuroendocrine tumors of the digestive tract: impact of new classifications and new agents on therapeutic approaches.
    Oberg K
    Curr Opin Oncol; 2012 Jul; 24(4):433-40. PubMed ID: 22510940
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Neuroendocrine tumors: the age of targeted therapies].
    Capdevila J; Argilés G; Mulet-Margalef N; Tabernero J
    Endocrinol Nutr; 2012; 59(7):438-51. PubMed ID: 22565119
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Novel therapeutic agents for the treatment of gastroenteropancreatic neuroendocrine tumors.
    Pavel ME; Wiedenmann B
    Horm Metab Res; 2011 Nov; 43(12):844-53. PubMed ID: 22105475
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Novel anticancer agents in clinical trials for well-differentiated neuroendocrine tumors.
    Faivre S; Sablin MP; Dreyer C; Raymond E
    Endocrinol Metab Clin North Am; 2010 Dec; 39(4):811-26. PubMed ID: 21095547
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Medical treatment of neuroendocrine tumours.
    Weber HC
    Curr Opin Endocrinol Diabetes Obes; 2013 Feb; 20(1):27-31. PubMed ID: 23221494
    [TBL] [Abstract][Full Text] [Related]  

  • 9. From targets to treatments: a review of molecular targets in pancreatic neuroendocrine tumors.
    Wiedenmann B; Pavel M; Kos-Kudla B
    Neuroendocrinology; 2011; 94(3):177-90. PubMed ID: 21893937
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pancreatic neuroendocrine tumors: targeting the molecular basis of disease.
    Khagi S; Saif MW
    Curr Opin Oncol; 2015 Jan; 27(1):38-43. PubMed ID: 25390554
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Therapy innovations: tyrosine kinase inhibitors for the treatment of pancreatic neuroendocrine tumors.
    Raymond E; Hobday T; Castellano D; Reidy-Lagunes D; García-Carbonero R; Carrato A
    Cancer Metastasis Rev; 2011 Mar; 30 Suppl 1():19-26. PubMed ID: 21308478
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of everolimus and sunitinib in patients with gastroenteropancreatic neuroendocrine tumor.
    Yoo C; Cho H; Song MJ; Hong SM; Kim KP; Chang HM; Chae H; Kim TW; Hong YS; Ryu MH; Kang YK; Kim SC; Ryoo BY
    Cancer Chemother Pharmacol; 2017 Jan; 79(1):139-146. PubMed ID: 27942928
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Medical Management of Pancreatic Neuroendocrine Tumors: Current and Future Therapy.
    Chan JA; Kulke MH
    Surg Oncol Clin N Am; 2016 Apr; 25(2):423-37. PubMed ID: 27013373
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Advances in the systemic treatment of neuroendocrine tumors in the era of molecular therapy.
    Leung R; Lang B; Wong H; Chiu J; Yat WK; Shek T; Cho WY; Yau LC; Yau T
    Anticancer Agents Med Chem; 2013 Mar; 13(3):382-8. PubMed ID: 23092266
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gastroenteropancreatic neuroendocrine tumors: update on therapeutics.
    Ganetsky A; Bhatt V
    Ann Pharmacother; 2012 Jun; 46(6):851-62. PubMed ID: 22589450
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Therapy innovation for the treatment of pancreatic neuroendocrine tumors.
    Riccardi F; Rizzo M; Festino L; Ambrosio F; Molino C; Uomo G; Cartenì G
    Expert Opin Ther Targets; 2012 Apr; 16 Suppl 2():S91-102. PubMed ID: 22372544
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Novel agents in gastroenteropancreatic neuroendocrine tumors.
    Stevenson R; Libutti SK; Saif MW
    JOP; 2013 Mar; 14(2):152-4. PubMed ID: 23474560
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Systemic therapy for advanced pancreatic neuroendocrine tumors.
    Kulke MH
    Semin Oncol; 2013 Feb; 40(1):75-83. PubMed ID: 23391115
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Management of gastroentero-pancreatic neuroendocrine tumors (GEP-NETs).
    Desai KK; Khan MS; Toumpanakis C; Caplin ME
    Minerva Gastroenterol Dietol; 2009 Dec; 55(4):425-43. PubMed ID: 19942827
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Molecular target therapy for gastroenteropancreatic neuroendocrine tumors].
    Inoue N; Komoto I; Awane M; Imamura M
    Nihon Rinsho; 2012 Nov; 70 Suppl 8():492-5. PubMed ID: 23513889
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 16.